RPG Life Sciences Limited announces an acquisition

Total consideration: RPG Active Pharma will acquire the API and Intermediates business undertaking of Raghava Life Sciences through a cash slump sale for up to Rs 135 Crores, subject to customary adjustments and applicable taxes. This is an asset/business acquisition, not a purchase of shares in Raghava Life Sciences. ^[1]

Revenue and margin comparison

The key analytical limitation is profitability disclosure: the acquisition filing reports the target’s revenue but provides no EBITDA or EBITDA-margin figure, while the cited coverage of RPG’s existing API business reports revenue but not its segment EBITDA margin. Accordingly, the acquisition can be sized against revenue, but its margin accretion or dilution cannot yet be assessed from reported data.

On the disclosed numbers, the maximum consideration equates to roughly 7.1x the target’s FY26 revenue—a derived sales multiple based on Rs 135 Crores divided by Rs 19 Crores. This should not be interpreted as an EBITDA multiple because target EBITDA is not reported.

Yes, but only at a high level. The transaction is a slump-sale acquisition by RPG Active Pharma Limited, RPG Life Sciences’ wholly owned subsidiary—not a purchase of Raghava Life Sciences’ shares. The assets being transferred include:

• Manufacturing facilities
• An R&D facility
• The API and intermediates business
• A portfolio of 29 API molecules: 22 commercialized and 7 under development ^[1]

The disclosure does not identify the facility locations, plant capacity, ownership or lease status, equipment being transferred, or the specific R&D infrastructure. Raghava’s separate CRO/CRAMS business is expressly excluded from the transaction. ^[1]

Regulatory status

As of the 2 September 2026 announcement, the transaction remained subject to regulatory approvals, including approvals from local authorities. Completion was expected within approximately 30 days, or such other period as mutually agreed, subject to closing conditions. ^[1]

Critically, the filing does not report:

• Current GMP certification status or certificate scope
• The certifying regulator or certificate validity
• Any recent GMP inspection outcome
• Regulatory observations, warning letters, or remediation requirements
• Whether existing product or site approvals will transfer automatically to RPG Active Pharma

Therefore, the facilities should be viewed as assets proposed for integration, with regulatory transfer and compliance status still requiring confirmation, rather than as facilities whose GMP standing has been established in the public disclosure. The acquired business will be housed in RPG Active Pharma’s operations, rather than transferred directly into RPG Life Sciences’ parent-company structure. ^[1]

The acquisition is expected to close within approximately 30 days of 2 September 2026—around 2 October 2026—or later if RPG Active Pharma and Raghava mutually agree, subject to satisfaction of the closing conditions. ^[1]

Key closing conditions

• Regulatory approvals: The transaction requires regulatory approvals, including approvals from relevant local authorities. The filing does not identify the specific authorities or approval types beyond this broad description. ^[1]
• Other closing conditions under the BTA: Completion is expressly conditional on satisfaction of the closing conditions agreed between the parties under the Business Transfer Agreement. The detailed conditions precedent are not separately disclosed in the regulatory announcement. ^[1]
• Third-party consents: No specific lender, customer, landlord, or other counterparty consents are separately named. The only broad reference is to regulatory approvals and local-authority approvals. ^[1]
• Transaction form: This is an acquisition of the API and intermediates business undertaking through a going-concern slump sale, rather than a share acquisition; therefore, no transfer of shares or change in shareholding is involved. ^[1]

Implication: The key timing risk is approval and closing-condition clearance rather than shareholder ownership transfer. The “30 days” is a tentative target, not a fixed completion date, and can extend by mutual agreement. ^[1]